Overview

Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)

Status:
RECRUITING
Trial end date:
2029-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and effectiveness of co-administered MDMA and psilocybin in military Veterans with a diagnosis of Posttraumatic Stress Disorder (PTSD). To apply or learn more, please view our website: https://hopkinspsychedelic.org/pamvet
Phase:
PHASE1
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
Gracias Family Foundation
Treatments:
N-Methyl-3,4-methylenedioxyamphetamine
Psilocybin